What should a patient do when a blood pressure prescription turns up in a recall notice? In the latest case, the urgent step is not throwing away the bottle or skipping a dose. It is checking whether the medication is actually part of the recall. The product involved is bisoprolol fumarate and hydrochlorothiazide, a generic form of Ziac used to treat high blood pressure. More than 11,000 bottles were pulled after testing found trace amounts of ezetimibe, a cholesterol medicine made by the same manufacturer.
The recall applies to the 2.5 mg/6.25 mg strength and only to bottles tied to lot numbers 17232401 and 17240974. It includes 30-count, 100-count, and 500-count bottles, with expiration dates in November 2025 and May 2026. Patients usually can confirm whether their prescription is affected by comparing the drug name, strength, lot number, and NDC on the label. The FDA categorized the action as Class III, meaning use of the product is not likely to cause harmful health consequences. That label matters because recalls are not all handled the same way. Some require immediate consumer action, while others are managed more narrowly at the wholesale or retail level. That distinction can help lower the panic that often follows the word “recall.”
Jennifer Young, PharmD, BCPS, CSP, lead medication safety specialist at the Institute for Safe Medication Practices, said, While recall notifications can be frightening, it’s important to contact your healthcare provider right away for advice before making any changes to your medication routine. The warning reflects how the drug works in daily treatment. Bisoprolol is a beta blocker that slows and steadies the heart, while hydrochlorothiazide helps the body remove extra sodium and water. When treatment for hypertension is interrupted without supervision, blood pressure control can become unstable, increasing the risk tied to poorly managed cardiovascular disease.
FDA guidance for patients follows the same logic. In many Class II and Class III recalls, people are generally advised to continue taking a medicine unless they receive different instructions from the company, a pharmacist, or a clinician. The reason is simple: for some patients, stopping treatment creates a more immediate risk than the defect behind the recall.
This is also not the first time a blood pressure drug recall has unsettled patients. Earlier recalls involving valsartan, losartan, and irbesartan were linked to different contamination concerns, but the practical advice stayed consistent. Patients were told to verify the exact lot, contact the pharmacy, and avoid changing therapy on their own. The FDA also notes that not every recall appears in headlines, because public notices are usually reserved for products with wider distribution or greater hazard.
For patients staring at a prescription bottle, the safest checklist stays short: confirm the strength, match the lot number, call the pharmacy or prescribing office, and keep taking the medicine unless a medical professional says otherwise. In this recall, the facts are limited, the risk category is low, and the biggest mistake is assuming every recall means an immediate stop.
